BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 23683568)

  • 1. Prevention of contrast-induced nephropathy by N-acetylcysteine in critically ill patients: different definitions, different results.
    Chousterman BG; Bouadma L; Moutereau S; Loric S; Alvarez-Gonzalez A; Mekontso-Dessap A; Laissy JP; Rahmouni A; Katsahian S; Brochard L; Schortgen F
    J Crit Care; 2013 Oct; 28(5):701-9. PubMed ID: 23683568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-acetylcysteine in preventing contrast-induced nephropathy assessed by cystatin C.
    Alioglu E; Saygi S; Turk U; Kirilmaz B; Tuzun N; Duman C; Tengiz I; Yildiz S; Ercan E
    Cardiovasc Ther; 2013 Jun; 31(3):168-73. PubMed ID: 22212518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
    Kim BJ; Sung KC; Kim BS; Kang JH; Lee KB; Kim H; Lee MH
    Int J Cardiol; 2010 Feb; 138(3):239-45. PubMed ID: 18793808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.
    Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM
    Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cystatin C and creatinine as markers for radiocontrast-induced nephropathy in patients treated with N-acetylcysteine.
    Merkle M; Sauter M; Argirov M; Wörnle M
    Ren Fail; 2010 Jan; 32(1):85-90. PubMed ID: 20113272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
    Allaqaband S; Tumuluri R; Malik AM; Gupta A; Volkert P; Shalev Y; Bajwa TK
    Catheter Cardiovasc Interv; 2002 Nov; 57(3):279-83. PubMed ID: 12410497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography.
    MacNeill BD; Harding SA; Bazari H; Patton KK; Colon-Hernadez P; DeJoseph D; Jang IK
    Catheter Cardiovasc Interv; 2003 Dec; 60(4):458-61. PubMed ID: 14624421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial.
    Thayssen P; Lassen JF; Jensen SE; Hansen KN; Hansen HS; Christiansen EH; Junker A; Ravkilde J; Thuesen L; Veien KT; Jensen LO
    Circ Cardiovasc Interv; 2014 Apr; 7(2):216-24. PubMed ID: 24714489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
    Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study.
    Huber W; Eckel F; Hennig M; Rosenbrock H; Wacker A; Saur D; Sennefelder A; Hennico R; Schenk C; Meining A; Schmelz R; Fritsch R; Weiss W; Hamar P; Heemann U; Schmid RM
    Radiology; 2006 Jun; 239(3):793-804. PubMed ID: 16714461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of contrast-induced nephropathy in patients with serum creatinine levels in the upper normal range by cystatin C: a prospective study in 374 patients.
    Wacker-Gußmann A; Bühren K; Schultheiss C; Braun SL; Page S; Saugel B; Schmid S; Mair S; Schoemig A; Schmid RM; Huber W
    AJR Am J Roentgenol; 2014 Feb; 202(2):452-8. PubMed ID: 24450691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of short-term infusion regimens of N-acetylcysteine plus intravenous fluids, sodium bicarbonate plus intravenous fluids, and intravenous fluids alone for prevention of contrast-induced nephropathy in the emergency department.
    Kama A; Yılmaz S; Yaka E; Dervişoğlu E; Doğan NÖ; Erimşah E; Pekdemir M
    Acad Emerg Med; 2014 Jun; 21(6):615-22. PubMed ID: 25039544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention.
    Ochoa A; Pellizzon G; Addala S; Grines C; Isayenko Y; Boura J; Rempinski D; O'Neill W; Kahn J
    J Interv Cardiol; 2004 Jun; 17(3):159-65. PubMed ID: 15209578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of intravenous n-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes.
    Jaffery Z; Verma A; White CJ; Grant AG; Collins TJ; Grise MA; Jenkins JS; McMullan PW; Patel RA; Reilly JP; Thornton SN; Ramee SR
    Catheter Cardiovasc Interv; 2012 May; 79(6):921-6. PubMed ID: 21542122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-Induced nephropathy: a prospective randomized study.
    Albabtain MA; Almasood A; Alshurafah H; Alamri H; Tamim H
    J Interv Cardiol; 2013 Feb; 26(1):90-6. PubMed ID: 22994682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
    Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
    Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of NaCl saline hydration and N-Acetyl Cysteine to prevent contrast induced nephropathy in different populations of patients at high and low risk undergoing coronary artery angiography.
    Calabrò P; Bianchi R; Caprile M; Sordelli C; Cappelli Bigazzi M; Palmieri R; Gigantino G; Limongelli G; Capozzi G; Cuomo S; Calabrò R
    Minerva Cardioangiol; 2010 Feb; 58(1):35-40. PubMed ID: 20145594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reno-protective effect of N-acetyl cysteine in patients with impaired renal function undergoing coronary angiography and interventions.
    Ramesh N; Pillai RK; Abraham T; Padmaja NP; Hameed S; Vijayaraghavan G
    J Assoc Physicians India; 2006 Jun; 54():449-52. PubMed ID: 16909692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity.
    Poletti PA; Saudan P; Platon A; Mermillod B; Sautter AM; Vermeulen B; Sarasin FP; Becker CD; Martin PY
    AJR Am J Roentgenol; 2007 Sep; 189(3):687-92. PubMed ID: 17715118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.